Biotech
Regeneron Pharmaceuticals, Inc.
5
Articles
Mentioned
Top Role
Feb 5, 2026
First Mention
Apr 11, 2026
Last Mention
6.81
Relevance Score
Intelligence Brief
Overview
Regeneron Pharmaceuticals is a biotech company focused on developing and commercializing medicines for serious diseases. Right now, they matter because of their strong presence in ophthalmology with Eylea and their strategic moves in RNAi therapeutics with Alnylam. Their ability to navigate the biosimilar pressures and maintain market share in key areas is critical.
Assets & Portfolio
Regeneron owns Eylea, a leading ophthalmology drug generating $9 billion annually. They also have a significant stake in the RNAi space through their partnership with Alnylam on Zilebesiran. Their infrastructure includes advanced biologics manufacturing capabilities and a robust clinical development engine.
Partnerships & Deals
Regeneron has a significant partnership with Alnylam to develop and commercialize Zilebesiran, sharing global profits 50/50 outside the U.S. This alliance leverages Alnylam's RNAi expertise and Regeneron's commercialization strength. Such partnerships are strategic to diversify their portfolio and mitigate risks associated with biosimilar competition.
Pipeline & Development
Regeneron's pipeline includes advancing Zilebesiran for cardiovascular indications. They are also focused on expanding indications for Eylea and exploring new therapeutic areas through collaborations. The pipeline reflects a balanced approach between maintaining strongholds and exploring new growth avenues.
Competitive Position
Regeneron is maintaining a strong competitive position in ophthalmology but faces increasing pressure from biosimilars. In oncology, they are recalibrating alongside peers like Merck and AstraZeneca due to competitive dynamics. Their strategic partnerships and focus on RNAi could provide a moat against some competitors.
Technology & Innovation
Regeneron is forward-looking in its technology adoption, particularly in biologics manufacturing and clinical development. However, there is insufficient evidence on their AI adoption compared to peers like J&J, who are heavily investing in AI drug discovery.
Growth Outlook
Regeneron's growth trajectory appears steady, driven by Eylea's performance and strategic expansions in RNAi. However, biosimilar pressures could impact growth if not managed effectively. Their ability to innovate and expand into new therapeutic areas will be crucial.
Industry Trend Fit
Regeneron's capabilities align with industry trends like RNAi therapeutics and the growing importance of biologics. However, their response to IRA pricing reforms and biosimilar challenges will test their adaptability. Their strategic partnerships suggest a proactive approach to these industry shifts.
Coverage Timeline
April 2026
Roche’s Lung Cancer Trial Upsets the Oncology Table: Market Dynamics and Competitor Response
The Week
Competitor
Apr 11, 2026
Across the landscape, Merck, Bristol Myers, Regeneron, AstraZeneca, pipeline teams are recalibrating.
Apr 11, 2026
Dr. Mathur is hardly an unknown quantity, her years running clinical strategy at Regeneron.
Biosimilars Beyond Humira: New Pressures and Unwritten Rules for Stelara, Keytruda, and Eylea in 2026
Pipeline
Primary Subject
Apr 11, 2026
Regeneron’s Eylea (aflibercept) is a $9 billion-a-year juggernaut in ophthalmology.
Regeneron and Alnylam’s $800M Bet: The Real Economics Behind Cardiovascular RNAi’s Next Blockbuster
The Week
Primary Subject
Apr 11, 2026
Regeneron will split global profits on Zilebesiran 50/50 outside of the U.S., and will co-develop and co-commercialize inside it.
February 2026
IRA Price Negotiation Year One: What the Numbers Reveal About CMS, Drugmakers, and the Real Deals
Policy
Mentioned
Feb 5, 2026
The reality: these drugs were uniquely vulnerable.